

# Yasuaki Sagara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/337415/publications.pdf>

Version: 2024-02-01

76  
papers

2,502  
citations

257450

24  
h-index

206112

48  
g-index

77  
all docs

77  
docs citations

77  
times ranked

3749  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. <i>Breast Cancer</i> , 2022, 29, 1-8.	2.9	6
2	ASO Visual Abstract: Satisfaction of Patients Who Received Breast-Conserving Surgery Using the Suture Scaffold Technique: A Single-Institution, Cross-Sectional Study. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
3	ASO Author Reflections: Patients's™ Satisfaction After Breast Conserving Surgery Using the Suture Scaffold Technique. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
4	Satisfaction of Patients Who Received Breast-Conserving Surgery Using the Suture Scaffold Technique: A Single-Institution, Cross-Sectional Study. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	3
5	The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial. <i>Surgical Oncology</i> , 2021, 36, 51-55.	1.6	4
6	Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study. <i>Breast Cancer</i> , 2021, 28, 896-903.	2.9	11
7	Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast Cancer. <i>Oncologist</i> , 2021, 26, e686-e693.	3.7	10
8	Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-expressing Advanced Breast Cancer: Results From a Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1887-1896.	1.6	465
9	Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 283-294.	2.5	34
10	National Patterns of Breast Reconstruction and Nipple-Sparing Mastectomy for Breast Cancer, 2005-2015. <i>Annals of Surgical Oncology</i> , 2019, 26, 3194-3203.	1.5	50
11	Alpelisib (ALP)+fulvestrant (FUL) in patients from Japan with advanced breast cancer: Subgroup analysis of SOLAR-1 trial. <i>Annals of Oncology</i> , 2019, 30, vi80.	1.2	0
12	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. <i>Lancet Oncology</i> , The, 2019, 20, 816-826.	10.7	252
13	Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 200-207.e1.	2.4	17
14	Impact of Topoisomerase II±, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 275-288.	2.5	27
15	Relation between dexamethasone (DEX) usage, preventive trimetprim/sulfamethoxazole (ST), and pneumocystis pneumonia (PCP) for patients with breast cancer receiving dose-dense AC followed by dose-dense paclitaxel (ddAC-ddP): Preplanned analysis of WJOG9016B.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12022-e12022.	1.6	4
16	Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 755-762.	2.3	8
17	Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY). <i>Breast Cancer</i> , 2018, 25, 438-446.	2.9	10
18	Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent diffusion coefficients and maximum standardized uptake values. <i>Japanese Journal of Radiology</i> , 2018, 36, 122-133.	2.4	15

#	ARTICLE	IF	CITATIONS
19	A genome-wide association study identifies three novel genetic markers for response to tamoxifen: A prospective multicenter study. <i>PLoS ONE</i> , 2018, 13, e0201606.	2.5	1
20	Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-CO3. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 675-683.	2.5	9
21	Maspin mRNA expression in sentinel lymph nodes predicts non-SLN metastasis in breast cancer patients with SLN metastasis. <i>Histopathology</i> , 2018, 73, 916-922.	2.9	4
22	Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341878624.	1.1	2
23	Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2501-2501.	1.6	68
24	Varying prognostic impact of molecular subtype among young patients with de novo stage IV breast cancer: A population-based cohort study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13090-e13090.	1.6	0
25	Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. <i>Annals of Surgery</i> , 2017, 265, 581-589.	4.2	238
26	Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis. <i>Cancer</i> , 2017, 123, 2609-2617.	4.1	4
27	Feasibility of Intraoperative Breast MRI and the Role of Prone Versus Supine Positioning in Surgical Planning for Breast-Conserving Surgery. <i>Breast Journal</i> , 2017, 23, 713-717.	1.0	19
28	Significant Effect of Polymorphisms in <i>CYP2D6</i> on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study. <i>Clinical Cancer Research</i> , 2017, 23, 2019-2026.	7.0	33
29	Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 709-723.	2.5	13
30	Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 583-592.	2.5	12
31	The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy. <i>Breast Cancer</i> , 2017, 24, 384-392.	2.9	3
32	A Retrospective Cohort Study to Investigate Association between Preferences for Future Care and Period of Final Chemotherapy Administration before End-of-Life. <i>Breast</i> , 2017, 36, S66.	2.2	0
33	Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast. <i>Frontiers in Oncology</i> , 2017, 7, 192.	2.8	25
34	Phyllodes Tumors of the Breast. , 2016, , 421-427.		0
35	Reply to K. Lin et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3485-3486.	1.6	0
36	Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 1-9.	2.5	45

#	ARTICLE	IF	CITATIONS
37	Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1190-1196.	1.6	114
38	Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 45-55.	2.5	8
39	Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 65-75.	2.5	30
40	Abstract 2031: Association between CYP2D6 genotype and response to tamoxifen in a prospective multicenter study in Japan. , 2016, , .		1
41	A low cost training phantom model for radioâ€­guided localization techniques in occult breast lesions. <i>Journal of Surgical Oncology</i> , 2015, 112, 449-451.	1.7	7
42	The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. <i>Cancer</i> , 2015, 121, 4333-4340.	4.1	23
43	Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ. <i>JAMA Surgery</i> , 2015, 150, 739.	4.3	157
44	Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. <i>Annals of Surgical Oncology</i> , 2015, 22, 4280-4286.	1.5	15
45	The Influence of Radiology Image Consultation in the Surgical Management of Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2015, 22, 3383-3388.	1.5	27
46	Modern Trends in the Surgical Management of Pagetâ€™s Disease. <i>Annals of Surgical Oncology</i> , 2015, 22, 3308-3316.	1.5	18
47	The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer. <i>Breast Cancer</i> , 2015, 22, 5-15.	2.9	13
48	F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. <i>Journal of Clinical Investigation</i> , 2015, 125, 621-635.	8.2	99
49	The utility of bi-weekly eribulin therapy for metastatic breast cancer: A Japanese multicenter phase II study (JUST-STUDY).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1026-1026.	1.6	1
50	Abstract P1-16-01: Effect of margin width on local recurrence in invasive lobular carcinoma treated with multimodality therapy. , 2015, , .		0
51	The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1006-1006.	1.6	0
52	Risk of axillary node metastasis in Paget disease with invasive ductal carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1054-1054.	1.6	0
53	Tumor subtype and race in male breast cancer: A population-based cohort study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 149-149.	1.6	0
54	Immediate breast volume replacement using a free dermal fat graft after breast cancer surgery: multi-institutional joint research of short-term outcomes in 262 Japanese patients. <i>Gland Surgery</i> , 2015, 4, 179-94.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Understanding process-of-care delays in surgical treatment of breast cancer at a comprehensive cancer center. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 125-133.	2.5	19
56	Pilot Study to Evaluate Feasibility of Image-Guided Breast-Conserving Therapy in the Advanced Multimodal Image-Guided Operating (AMIGO) Suite. <i>Annals of Surgical Oncology</i> , 2014, 21, 3356-3357.	1.5	12
57	Incidence of contralateral breast cancer in Japanese patients with unilateral minimum-risk primary breast cancer, and the benefits of endocrine therapy and radiotherapy. <i>Breast Cancer</i> , 2014, 21, 284-291.	2.9	9
58	Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast. <i>Cancer Science</i> , 2014, 105, 1503-1509.	3.9	9
59	Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 (BOOSTER) trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS657-TPS657.	1.6	1
60	Change in breast density as a response to adjuvant endocrine treatment: An American cohort.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11523-e11523.	1.6	0
61	Clinical application of the one-step nucleic acid amplification method to detect sentinel lymph node metastasis in breast cancer. <i>Breast Cancer</i> , 2013, 20, 181-186.	2.9	33
62	Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer. <i>Cancer</i> , 2013, 119, 704-713.	4.1	20
63	Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SC 1001). <i>Molecular and Clinical Oncology</i> , 2013, 1, 47-52.	1.0	6
64	Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial. <i>Oncology Reports</i> , 2013, 29, 1707-1713.	2.6	33
65	Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer. <i>British Journal of Cancer</i> , 2012, 107, 1239-1243.	6.4	44
66	Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 345-352.	10.7	147
67	519 Intraoperative One-step Nucleic Acid Amplification Assay(OSNA) to Detect Sentinel Lymph Node(SLN) Metastasis in Breast Cancer—an Evaluation of 703 Cases in a Single Institution. <i>European Journal of Cancer</i> , 2012, 48, S198.	2.8	1
68	Study on the state of implementation of HER2 testing and positive ratios in patients with breast cancer in the Kyushu-Okinawa region of Japan. <i>Breast Cancer</i> , 2012, 19, 315-320.	2.9	2
69	Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study. <i>Histopathology</i> , 2011, 58, 608-616.	2.9	48
70	Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. <i>Histopathology</i> , 2011, 59, 776-780.	2.9	75
71	Mucocele-like lesions of the breast: a long-term follow-up study. <i>Diagnostic Pathology</i> , 2011, 6, 29.	2.0	19
72	Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer. <i>Diagnostic Pathology</i> , 2011, 6, 36.	2.0	26

#	ARTICLE	IF	CITATIONS
73	Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients. <i>Breast Cancer</i> , 2010, 17, 212-217.	2.9	9
74	Clear cell hidradenoma of the breast: a case report with review of the literature. <i>Breast Cancer</i> , 2007, 14, 307-311.	2.9	32
75	Team approach to providing the multidisciplinary medical treatment derived by the patients and their family. <i>Breast Cancer</i> , 2005, 12, 21-25.	2.9	5
76	Identification of molecular markers for metastasis-related genes in primary breast cancer cells. <i>Clinical and Experimental Metastasis</i> , 2005, 22, 59-67.	3.3	41